309 related articles for article (PubMed ID: 15292285)
1. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.
Sawka AM; Thephamongkhol K; Brouwers M; Thabane L; Browman G; Gerstein HC
J Clin Endocrinol Metab; 2004 Aug; 89(8):3668-76. PubMed ID: 15292285
[TBL] [Abstract][Full Text] [Related]
2. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.
Sawka AM; Brierley JD; Tsang RW; Thabane L; Rotstein L; Gafni A; Straus S; Goldstein DP
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):457-80, x. PubMed ID: 18502337
[TBL] [Abstract][Full Text] [Related]
3. The Effectiveness of Radioactive Iodine Remnant Ablation for Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis.
Hu G; Zhu W; Yang W; Wang H; Shen L; Zhang H
World J Surg; 2016 Jan; 40(1):100-9. PubMed ID: 26578322
[TBL] [Abstract][Full Text] [Related]
4. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma.
Lin JD; Kao PF; Chao TC
Br J Radiol; 1998 Mar; 71(843):307-13. PubMed ID: 9616241
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008.
Sacks W; Fung CH; Chang JT; Waxman A; Braunstein GD
Thyroid; 2010 Nov; 20(11):1235-45. PubMed ID: 21062195
[TBL] [Abstract][Full Text] [Related]
7. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
9. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma.
Mazzaferri EL
Thyroid; 1997 Apr; 7(2):265-71. PubMed ID: 9133698
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
[TBL] [Abstract][Full Text] [Related]
11. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
[TBL] [Abstract][Full Text] [Related]
12. [CME: Radioactive iodine therapy in thyroid cancer].
Steinert HC; Aberle S
Praxis (Bern 1994); 2015 Nov; 104(23):1235-43; quiz 1244-5. PubMed ID: 26558927
[TBL] [Abstract][Full Text] [Related]
13. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
14. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
15. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States.
Wang TS; Cheung K; Mehta P; Roman SA; Walker HD; Sosa JA
J Clin Endocrinol Metab; 2010 Apr; 95(4):1672-80. PubMed ID: 20139234
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
17. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
18. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
19. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study.
Mäenpää HO; Heikkonen J; Vaalavirta L; Tenhunen M; Joensuu H
PLoS One; 2008 Apr; 3(4):e1885. PubMed ID: 18382668
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine remnant ablation in papillary thyroid microcarcinoma: a meta-analysis.
Yang T; Zheng SY; Jiao J; Zou Q; Zhang Y
Nucl Med Commun; 2019 Jul; 40(7):711-719. PubMed ID: 31095043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
